Schizophrenia Trial, Recruiting NCT05661448 Sponsor: Douglas Mental Health University Institute Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT05661448
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a psychotic disorder or a related mental health condition (such as affective or non-affective psychosis)
  • People who are currently being seen and treated by a clinician at one of the participating services
  • People whose symptoms are stable enough, and who are able to use online platforms and take part in group sessions, as determined by their psychiatrist or case manager
  • People who have access to a private space, such as a room where they can be alone, to keep group sessions confidential
  • People who are able to provide an emergency contact and agree to allow researchers to contact their clinician and/or emergency services if needed during the study

Who may not be able to join:

  • People who have an intellectual disability
  • People who are currently hospitalised at the time of recruitment
  • People who are unable to speak or read English or French
  • People who are assessed as being at high risk of suicide at the time of evaluation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Martin Lepage, Douglas Mental Health University Institute

Phone: (514) 761-6131

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Douglas Mental Health University Institute
Registry
ClinicalTrials.gov
Start date
15 April 2023
Est. completion
31 August 2029

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change from Baseline Brief version of the Cambridge Neuropsychological Testing Automated Battery (CANTAB) score at the end of the intervention; Change from Baseline Wechsler Memory Scale - Logical Memory (LM) subscale score at the end of the intervention; Change from Baseline Brief Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS-B) score at the end of the intervention; Change from Baseline Cognitive Motivation Scale (CMS) score at the end of the intervention; Change from Baseline Davos Assessment of Cognitive Biases Scale (DACOBS) score at the end of the intervention; Change...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov